Shenzhen TargetRx

Shenzhen TargetRx is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation small molecule targeted therapies, with a primary focus on overcoming acquired drug resistance in oncology. The company utilizes a proprietary structure-based drug design platform to develop highly selective inhibitors for validated targets such as ALK, ROS1, and BCR-ABL. Its lead candidates, TGRX-326 and TGRX-678, are currently in clinical development for the treatment of non-small cell lung cancer and chronic myeloid leukemia, respectively. TargetRx aims to address significant unmet medical needs by providing potent therapeutic options for patients who have failed previous lines of targeted therapy.